Cargando…

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

BACKGROUND: Despite the positive impact of targeted therapies on metastatic renal cell carcinoma (mRCC), durable responses are infrequent and an unmet need exists for novel therapies with distinct mechanisms of action. We investigated the combination of recombinant Interleukin 21 (IL-21), a cytokine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatia, Shailender, Curti, Brendan, Ernstoff, Marc S, Gordon, Michael, Heath, Elisabeth I, Miller, Wilson H, Puzanov, Igor, Quinn, David I, Flaig, Thomas W, VanVeldhuizen, Peter, Byrnes-Blake, Kelly, Freeman, Jeremy A, Bittner, Rachel, Hunder, Naomi, Souza, Sonia, Thompson, John A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019894/ https://www.ncbi.nlm.nih.gov/pubmed/24829759 http://dx.doi.org/10.1186/2051-1426-2-2

Ejemplares similares

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
por: Trédan, Olivier, et al.
Publicado: (2023)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
por: Silk, Ann W., et al.
Publicado: (2023)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
por: Clark, Joseph I., et al.
Publicado: (2018)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

PluS Nanoparticles Loaded with Sorafenib: Synthetic Approach and Their Effects on Endothelial Cells
por: Palomba, Francesco, et al.
Publicado: (2019)

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?
por: Adhoute, Xavier, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells
por: Cao, J.Y., et al.
Publicado: (2017)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

COVID-19 and Cancer: a Comprehensive Review
por: Gosain, Rohit, et al.
Publicado: (2020)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
por: Assenat, Eric, et al.
Publicado: (2019)

Leiomyosarcoma of the inferior vena cava: a case report and review of the literature
por: Reddy, Venkataprasanth P, et al.
Publicado: (2010)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
por: Jonasch, Eric, et al.
Publicado: (2023)

Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)
por: Daud, Adil, et al.
Publicado: (2015)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
por: Chapuis, Aude G., et al.
Publicado: (2016)

Transcatheter Arterial Chemoembolization and Chemotherapy plus Sorafenib in a Large Hepatocellular Carcinoma with Arterioportal Shunt
por: Chen, Jun, et al.
Publicado: (2014)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report
por: Appelbaum, Jacob, et al.
Publicado: (2018)

Chemoembolization Plus Radiotherapy versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis
por: Chu, Hee Ho, et al.
Publicado: (2020)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Lin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rubh7vk1surp7nd6bl7atf4kj8